Nippon Shinyaku Valuation Multiples

Nippon Shinyaku Overview

About Nippon Shinyaku

Nippon Shinyaku Co Ltd is engaged in the pharmaceuticals and functional food businesses. The Pharmaceuticals Business develops and sells treatments for urological disorders, blood cancer, rare and intractable diseases, and gynecological conditions. The Functional Food Business produces and sells health food ingredients, quality-stabilizing preservatives, protein preparations, and supplements. It generates the majority of its revenue from the Pharmaceuticals segment.

Founded

1919

HQ

Employees

2.2K

Website

nippon-shinyaku.co.jp

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $1B

EBITDA: $264M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Nippon Shinyaku Financials

Nippon Shinyaku reported last 12-month revenue of $1B and EBITDA of $264M.

In the same LTM period, Nippon Shinyaku generated $716M in gross profit, $264M in EBITDA, and $174M in net income.

Nippon Shinyaku P&L

In the most recent fiscal year, Nippon Shinyaku reported revenue of $1B and EBITDA of $286M.

Nippon Shinyaku expects next 12-month revenue of XXX and NTM EBITDA of XXX

Nippon Shinyaku Stock Performance

Nippon Shinyaku has current market cap of $2B, and enterprise value of $2B.

Nippon Shinyaku's stock price is $32.10.

Nippon Shinyaku Valuation Multiples

Nippon Shinyaku trades at 1.6x EV/Revenue multiple, and 6.8x EV/EBITDA.

Nippon Shinyaku Financial Valuation Multiples

As of April 19, 2026, Nippon Shinyaku has market cap of $2B and EV of $2B.

Equity research analysts estimate Nippon Shinyaku's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Nippon Shinyaku has a P/E ratio of 12.4x.

Nippon Shinyaku Margins & Growth Rates

Nippon Shinyaku's revenue in the last 12 month grew by 10%.

Nippon Shinyaku's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

Nippon Shinyaku's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Nippon Shinyaku's rule of X is 46% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Nippon Shinyaku Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Nippon Shinyaku M&A Activity

Nippon Shinyaku acquired XXX companies to date.

Last acquisition by Nippon Shinyaku was on XXXXXXXX, XXXXX. Nippon Shinyaku acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Nippon Shinyaku Investment Activity

Nippon Shinyaku invested in XXX companies to date.

Nippon Shinyaku made its latest investment on XXXXXXXX, XXXXX. Nippon Shinyaku invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).